Herpesvirus Antiviral Resistance
Database


    • TOP

    Lundgren J

    Mutations:

    Mutant Gene Virus Reference
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    E596Q UL97 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)